ImmunityBio announced a study originating from Culver City.
3 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ImmunityBio announced a study originating from Culver City.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ImmunityBio
biotech company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that
- Insider MonkeyImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results We recently published 10 Stocks With Whopping 11-97% Upside. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stock
- Business WireImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy Single-agent CD19 CAR-NK cell therapy achieved a c